AstraZeneca: Heart Failure trials

The registry lists 64 Heart Failure studies with AstraZeneca as lead sponsor. 6 are open to participants now and 14 have results posted.

Phase 1 13Phase 2 9Phase 3 16Phase 4 2No phase 25(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFRecruitingNCT07761117Phase 3
• Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CMRecruitingNCT07690436
• Tezspire Cardiac Events PASSRecruitingNCT06951867
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinRecruitingNCT06677060Phase 3
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionRecruitingNCT06307652Phase 3
• iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesRecruitingNCT03549754
• A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2CompletedNCT05737940Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%CompletedNCT04986202Phase 2/3Results posted
• Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney DiseaseCompletedNCT04595370Phase 2Results posted
• Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.CompletedNCT04564742Phase 3Results posted
• Study of Verinurad in Heart Failure With Preserved Ejection FractionCompletedNCT04327024Phase 2Results posted
• DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection FractionCompletedNCT03877237Phase 3Results posted
• DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection FractionCompletedNCT03877224Phase 3Results posted
• Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.TerminatedNCT03756285Phase 2Results posted
• Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.CompletedNCT03619213Phase 3Results posted
• Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart FailureTerminatedNCT03532009Phase 2Results posted
• AZD8601 Study in CABG PatientsCompletedNCT03370887Phase 2Results posted
• Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart FailureCompletedNCT03036124Phase 3Results posted
• Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart FailureCompletedNCT02917031Phase 4Results posted
• Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs AloneCompletedNCT00391846Phase 4Results posted
• A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462CompletedNCT06989983Phase 1
• Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in GermanyActive, not recruitingNCT06675552
• A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal ImpairmentTerminatedNCT06639087Phase 1
• A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.TerminatedNCT06381466Phase 1
• Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in RussiaTerminatedNCT06338839
• Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in GermanyActive, not recruitingNCT06336330
• A Phase IIb Study of AZD5462 in Patients With Chronic Heart FailureCompletedNCT06299826Phase 2
• A Study to Assess Multidomain Endpoints of an ECG PatchCompletedNCT06243029
• Real-world Dapagliflozin Experience in Patients With Heart Failure in GreeceCompletedNCT05635331
• Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)CompletedNCT05465213
• PORTHOS - PORTuguese Heart Failure Observational StudyCompletedNCT05434923
• Tracking Treatment Pathways in Adult Patients With Hyperkalemia.CompletedNCT05408039
• Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom.CompletedNCT05188144
• Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium LevelsCompletedNCT05184998
• A Study on Disease Awareness and Treatment Compliance of Heart Failure PatientsCompletedNCT05180396
• Multicenter Prospective Observational Study Evaluating the Management of Heart FailureCompletedNCT05180370
• Dapagliflozin Post Marketing Surveillance in HF and CKDCompletedNCT05134701
• Study to Evaluate the Effects of AZD3427 in Patients With Heart FailureWithdrawnNCT04890548Phase 1
• Forxiga HF General Drug Use-Results StudyCompletedNCT04865406
• Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy VolunteersCompletedNCT04798222Phase 1
• Heart Failure Patients RegistryCompletedNCT04709263
• Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427CompletedNCT04630067Phase 1
• A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy VolunteersCompletedNCT04232345Phase 1
• An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes PatientsCompletedNCT04072523
• A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy VolunteersCompletedNCT03843060Phase 1
• A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male SubjectsCompletedNCT03804645Phase 1
• A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose AdministrationCompletedNCT03801967Phase 1
• Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum PotassiumTerminatedNCT03682497Phase 1
• A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male SubjectsCompletedNCT03450759Phase 1
• Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male SubjectsCompletedNCT03435276Phase 1
• A Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in IndiaWithdrawnNCT02047526
• An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHFCompletedNCT01455402
• Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and PrasugrelCompletedNCT01276275
• Economic Evaluation of Heart Failure Management in Colombian ClinicsCompletedNCT01084564
• National Survey on Coronary Patients and Heart Failure Performed in 2 Patient GroupsCompletedNCT00699959
• Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in FranceCompletedNCT00679640
• Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)CompletedNCT00634712Phase 3
• Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)CompletedNCT00634400Phase 3
• Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)CompletedNCT00634309Phase 3
• Rosuvastatin Impact on Ventricular Remodelling Lipids and CytokinesCompletedNCT00240292Phase 3
• Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub StudyCompletedNCT00228514Phase 3
• Crestor Versus Placebo in Subjects With Heart FailureCompletedNCT00206310Phase 3
• PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart FailureCompletedNCT00099580Phase 2
• Reversal of Ventricular Remodeling With Toprol-XLCompletedNCT00038077Phase 3